Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biontech Se ADR (NQ: BNTX )

118.39 -2.33 (-1.93%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
65 66 Next >
BioNTech's Revenue Triples On Omicron Demand For Its Pfizer-Partnered Covid Shot
BioNTech beat first-quarter sales expectations by more than $2 billion. 
Via Investor's Business Daily
BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance
Via Benzinga
Recap: BioNTech Q1 Earnings
BioNTech (NASDAQ:BNTX) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings BioNTech reported an EPS of $15.97. 
Via Benzinga
Palantir, Plug Power, Novavax, BioNTech, Lordstown: 5 Key Earnings To Watch Today
The first-quarter reporting season is well and truly underway. 
Via Benzinga
5 Stocks To Watch For May 9, 2022
Some of the stocks that may grab investor focus today are: 
Via Benzinga
Bulls Look To Bounce Back After Bear Barrage
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
What's Happening With BioNTech SE Shares?
Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China. 
Via Benzinga
S&P 500 and Dow Lose 3% While Nasdaq Composite Slides 5%
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
FDA Limits Use of Johnson & Johnson's COVID-19 Vaccine to Certain Individuals - All You Should Know
The FDA said it was limiting the use of Johnson & Johnson's (NYSE: 
Via Benzinga
7 Dividend-Paying Large-Cap Stocks to Buy in May
These dividend-paying large-cap stocks offer an attractive buffer against the current macro-economic climate. 
Via InvestorPlace
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months... 
Via Benzinga
Textbook Company's Results Show Students Are Hitting The Job Market Instead Of The Books
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
US Study Shows Omicron As Severe As Previous COVID Variants: Reuters
Via Benzinga
Pfizer: The Treasure of Albert Bourla
Pfizer won the lottery with Covid-19, but how it invests that cash will determine how well the stock does in the longer-term. 
Via InvestorPlace
Lyft And Uber Battle Over Earnings Ahead Of The Fed Announcement
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Bulls Try To Build On Yesterday's Gains But Looming Fed Decision Could Curb Trading
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters
Via Benzinga
April's Sell-Off Continues Into May As Futures Point To A Lower Open
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Disappointing Earnings And A Spike In Inflation Send Stocks Plunging
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 2
CNBC Fourth COVID-19 Shot? See Why Medical Professionals Are Skeptical Medical professionals are undecided on whether a fourth dose of the Covid-19 vaccine would benefit the... 
Via Benzinga
Fourth COVID-19 Shot? See Why Medical Professionals Are Skeptical
Medical professionals are undecided on whether a fourth dose of the Covid-19 vaccine would benefit the wider population, as countries are beginning to offer the fourth dose to vulnerable groups. 
Via Benzinga
FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA
Via Benzinga
Novavax Surges As Its Covid Shot Approaches The FDA Finish Line
The FDA advisory committee will meet June 7 to discuss its Covid shot. 
Via Investor's Business Daily
Morning Brief: Top Financial Stories Dominating on Thursday, April 28
CNBC Ford Motor Slashes 580 Jobs, Mainly In Engineering Ford Motor Co (NYSE: F) is slashing 580 U.S. salaried employees and agency workers as part of its ongoing Ford+... 
Via Benzinga
Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg
At least six U.S. states are reporting confirmed or suspected cases of an unexplained, severe liver disorder in children. Health officials in New York state and Wisconsin said they’re investigating... 
Via Benzinga
Market Briefing For Thursday, April 28
Strategizing trading in this market is virtually a fool's errand; nevertheless a lot of folks continue debating the trading dynamics as if to catch anything of an important nature. 
Via Talk Markets
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years
Via Benzinga
Market Briefing For Tuesday, April 26
The current risk of 'revolution' in China or famine in many parts of the 3rd world due to COVID or war, does not appear to be adequately realized by markets or governments. 
Via Talk Markets
Poland, Moderna Working Towards Increased Flexibility Of COVID-19 Vaccine Contracts: Reuters
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.